References
- NIOSH. 2018. Development of the Inventory of 9/11 Agents. Washington DC: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health. https://wwwn.cdc.gov/ResearchGateway/Content/pdfs/Development_of_the_Inventory_of_9-11_Agents_20180717.pdf.
- Boffetta P, Hall CB, Todd AC, et al. Cancer risk among World Trade Center rescue and recovery workers: a review. CA Cancer J Clin. 2022;72(4):308–314. doi:10.3322/caac.21723.
- Santiago-Colón A, Daniels R, Reissman D, et al. World Trade Center Health Program: first decade of research. IJERPH. 2020;17(19):7290. PMID: 33036199; PMCID: PMC7579473 doi:10.3390/ijerph17197290.
- NIOSH. 2015a. Policy and procedures for certification of physician determinations for aerodigestive and cancer health conditions. Washington DC: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health. https://www.cdc.gov/wtc/pdfs/policies/WTCHPPPCertPhysDetFINAL20Feb2015-508.pdf.
- CDC. World Trade Center Health Program; Addition of Certain Types of Cancer to the List of WTC-Related Health Conditions. Proposed rule. Fed Regist. 2012a;77(114):35574–35615 (to be codified at 42 CFR Part 88). https://www.govinfo.gov/content/pkg/FR-2012-06-13/pdf/2012-14203.pdf.
- CDC. World Trade Center Health Program; Addition of Certain Types of Cancer to the List of WTC-Related Health Conditions. Final rule. Fed Regist. 2012b;77(177):56138–56168 (to be codified at 42 CFR Part 88). https://www.govinfo.gov/content/pkg/FR-2012-09-12/pdf/2012-22304.pdf.
- CDC. World Trade Center Health Program; Addition of Uterine Cancer to the List of WTC-Related Health Conditions. Final rule. Fed Regist. 2023;88(11):2845–2858 (to be codified at 42 CFR Part 88). https://www.govinfo.gov/content/pkg/FR-2023-01-18/pdf/2023-00645.pdf.
- NIOSH. 2022. Program Statistics: World Trade Center Health Program. Cincinnati, OH: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health. https://www.cdc.gov/wtc/ataglance.html.
- Calvert GM, Anderson K, Cochran J, et al. The World Trade Center Health Program: An introduction to best practices. Arch Environ Occup Health. 2022;19:1–7. Epub ahead of print. doi:10.1080/19338244.2022.2156975.
- USPSTF. 2018. Grade Definitions. Rockville, MD: U.S. Preventive Services Task Force, https://uspreventiveservicestaskforce.org/uspstf/about-uspstf/methods-and-processes/grade-definitions.
- Siu AL; U.S. Preventive Services Task Force. Screening for breast cancer: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med. 2016;164(4):279–296. doi:10.7326/M15-2886.
- US Preventive Services Task Force; Krist AH, Davidson KW, Mangione CM, et al. Screening for lung cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2021;325(10):962–970. doi:10.1001/jama.2021.1117.
- US Preventive Services Task Force, Curry SJ, Krist AH, Owens DK, et al. Screening for cervical cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2018;320(7):674–686. doi:10.1001/jama.2018.10897.
- US Preventive Services Task Force, Davidson KW, Barry MJ, Mangione CM, et al. Screening for colorectal cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2021;325(19):1965–1977. doi:10.1001/jama.2021.6238.
- Hall IJ, Tangka FKL, Sabatino SA, Thompson TD, Graubard BI, Breen N. Patterns and trends in cancer screening in the United States. Prev Chronic Dis. 2018;15:E97. doi:10.5888/pcd15.170465.
- WHO. 2014. Comprehensive cervical cancer control: a guide to essential practice. 2nd ed. Geneva: World Health Organization. https://www.ncbi.nlm.nih.gov/books/NBK269601/.
- Perkins RB, Guido RS, Castle PE, et al.; 2019 ASCCP Risk-Based Management Consensus Guidelines Committee. 2019 ASCCP risk-based management consensus guidelines for abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis. 2020;24(2):102–131. Erratum in: J Low Genit Tract Dis. 24(4):427. doi:10.1097/LGT.0000000000000525.
- WHO. 2021. WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention. 2nd ed. Geneva: World Health Organization. https://www.who.int/publications/i/item/9789240030824.
- Atkin W, Wooldrage K, Parkin DM, et al. Long term effects of once-only flexible sigmoidoscopy screening after 17 years of follow-up: the UK Flexible Sigmoidoscopy Screening randomised controlled trial. Lancet. 2017;389(10076):1299–1311. doi:10.1016/S0140-6736(17)30396-3.
- Zauber AG, Winawer SJ, O'Brien MJ, et al. Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. N Engl J Med. 2012;366(8):687–696. doi:10.1056/NEJMoa1100370.
- Miller EA, Pinsky PF, Schoen RE, Prorok PC, Church TR. Effect of flexible sigmoidoscopy screening on colorectal cancer incidence and mortality: long-term follow-up of the randomised US PLCO cancer screening trial. Lancet Gastroenterol Hepatol. 2019;4(2):101–110. doi:10.1016/S2468-1253(18)30358-3.
- Gupta S, Lieberman D, Anderson JC, et al. Recommendations for follow-up after colonoscopy and polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer. Am J Gastroenterol. 2020;115(3):415–434. doi:10.14309/ajg.0000000000000544.
- Hoffman RM, Reuland DS, Volk RJ. The Centers for Medicare & Medicaid Services requirement for shared decision-making for lung cancer screening. JAMA. 2021;325(10):933–934. doi:10.1001/jama.2021.1817.
- Fedewa SA, Kazerooni EA, Studts JL, et al. State variation in low-dose computed tomography scanning for lung cancer screening in the United States. J Natl Cancer Inst. 2021;113(8):1044–1052. doi:10.1093/jnci/djaa170.
- CMS. 2015. Decision Memo: Screening for Lung Cancer with Low Dose Computed Tomography (LDCT). Baltimore, MD: U.S. Centers for Medicare & Medicaid Services. Available at https://www.cms.gov/medicare-coverage-database/view/ncacal-decision-memo.aspx?proposed=N&NCAId=274. Accessed July 19, 2022.
- Volk RJ, Lowenstein LM, Leal VB, et al. Effect of a patient decision aid on lung cancer screening decision-making by persons who smoke: a randomized clinical trial. JAMA Netw Open. 2020;3(1):e1920362. doi:10.1001/jamanetworkopen.2019.20362.
- Doubeni CA, Gabler NB, Wheeler CM, et al. Timely follow-up of positive cancer screening results: a systematic review and recommendations from the PROSPR Consortium. CA Cancer J Clin. 2018;68(3):199–216. doi:10.3322/caac.21452.
- Sarma EA, Walter FM, Kobrin SC. Achieving diagnostic excellence for cancer: symptom detection as a partner to screening. JAMA. 2022;328(6):525–526. doi:10.1001/jama.2022.11744.
- Chapman D, Poirier V, Vulkan D, et al.; ACE MDC projects. First results from five multidisciplinary diagnostic centre (MDC) projects for non-specific but concerning symptoms, possibly indicative of cancer. Br J Cancer. 2020;123(5):722–729. doi:10.1038/s41416-020-0947-y.
- Kinsinger LS, Anderson C, Kim J, et al. Implementation of lung cancer screening in the Veterans Health Administration. JAMA Intern Med. 2017;177(3):399–406. doi:10.1001/jamainternmed.2016.9022.
- MacMahon H, Naidich DP, Goo JM, et al. Guidelines for management of incidental pulmonary nodules detected on CT images: from the Fleischner Society 2017. Radiology. 2017;284(1):228–243. doi:10.1148/radiol.2017161659.
- NIOSH. 2015b. Minimum Latency & Types or Categories of Cancer. Washington DC: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health. https://www.cdc.gov/wtc/pdfs/policies/WTCHP-Minimum-Cancer-Latency-PP-01062015-508.pdf.